Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3041658
Eltrekibart · 4 trials · 5 indications
The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.
| Arm | Type | Description |
|---|---|---|
| Eltrekibart + Placebo | EXPERIMENTAL | Participants will receive eltrekibart with placebo, eltrekibart or mirikizumab. |
| Mirikizumab + Placebo | EXPERIMENTAL | Participants will receive mirikizumab and placebo or mirikizumab. |
| Eltrekibart + Mirikizumab | EXPERIMENTAL | Participants will receive eltrekibart and mirikizumab in combination or separately as monotherapy. |
| Placebo | EXPERIMENTAL | Participants will receive placebo or mirikizumab. |
| Eltrekibart Dose 1 | EXPERIMENTAL | Eltrekibart will be given subcutaneously (SC). |
| Eltrekibart Dose 2 | EXPERIMENTAL | Eltrekibart will be given SC. |
| Eltrekibart Dose 3 | EXPERIMENTAL | Eltrekibart will be given SC. |
| LY3041658 | EXPERIMENTAL | Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W). |
| Name | Type | Description |
|---|---|---|
| Eltrekibart | DRUG | Administered |
| Mirikizumab | DRUG | Administered |
| Placebo | DRUG | Administered |
| LY3041658 | DRUG | Administered IV |
Inclusion Criteria: * Have had an established diagnosis of UC of ≥3 months in duration before baseline. * Have moderately to severely active UC as assessed by the UC disease activity score. * Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib, Lutikizumab |
| Incyte Corporation | INCY | 6 | PHASE3 | povorcitinib, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Remibrutinib, Secukinumab |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE2 | Duvakitug, Brivekimig, SAR445399 |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Olatorepatide |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY072 |
| Oruka Therapeutics, Inc. | ORKA | 1 | PHASE2 | ORKA-002 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE1 | SAR447971 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE1 | Soquelitinib |
Eltrekibart is an investigational small molecule being developed by Eli Lilly and Company for inflammatory conditions. It is in Phase 2 clinical development for hidradenitis suppurativa and ulcerative colitis. Eltrekibart has been studied in a completed Phase 2 trial in hidradenitis suppurativa and an active Phase 2 trial in ulcerative colitis.
Eltrekibart is being evaluated for the treatment of hidradenitis suppurativa and ulcerative colitis. It is an investigational therapy and has not been approved for any indication. Clinical trials have enrolled adults with moderate to severe hidradenitis suppurativa and moderately to severely active ulcerative colitis.
Eltrekibart is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Eli Lilly is conducting the clinical development program for eltrekibart in hidradenitis suppurativa and ulcerative colitis.
Eltrekibart is in Phase 2 clinical development. A Phase 2 trial in hidradenitis suppurativa has been completed, and a Phase 2 trial in ulcerative colitis is active but not recruiting. Eltrekibart is investigational and has not been approved by the FDA for any indication.
Eltrekibart has been studied in two Phase 2 trials. NCT06046729 evaluated eltrekibart in adults with moderate to severe hidradenitis suppurativa and has completed with 352 participants. NCT06598943 is evaluating eltrekibart and mirikizumab in adults with moderately to severely active ulcerative colitis and is active but not recruiting, with 143 participants.
Yes, LY3041658 is an alternative designation for eltrekibart. The Phase 2 hidradenitis suppurativa trial NCT06046729 refers to the drug as eltrekibart (LY3041658). Both names refer to the same investigational compound being developed by Eli Lilly and Company.